MedPath
HSA Approval

RUPAFIN ORAL SOLUTION 1mg/ml

SIN14868P

RUPAFIN ORAL SOLUTION 1mg/ml

RUPAFIN ORAL SOLUTION 1mg/ml

October 9, 2015

HYPHENS PHARMA PTE. LTD.

HYPHENS PHARMA PTE. LTD.

Regulatory Information

HYPHENS PHARMA PTE. LTD.

HYPHENS PHARMA PTE. LTD.

Therapeutic

Prescription Only

Formulation Information

SOLUTION

**4.2 Posology and method of administration** Children aged 2 to 11 years. _Dosage in children weighing equal or more than 25 kg:_ 5 ml (5 mg of rupatadine) of oral solution once a day, with or without food. _Dosage in children weighing equal or more than 10kg up to less than 25kg:_ 2.5ml (2.5mg of rupatadine) of oral solution once a day, with or without food. The administration of the product to children aged under 2 years is not recommended due to the lack of data in this population (see section 4.4 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). In adults and adolescents (over 12 years of age), the administration of rupatadine 10 mg tablets is more appropriate. Patients with renal or hepatic insufficiency: As there is no clinical experience in patients with impaired kidney or liver functions, the use of rupatadine is at present not recommended in these patients. _Instructions of use:_ - To open the bottle press the cap and turn it anticlockwise. - Take the syringe and put it in the perforated stopper and turn the bottle upside down. - Fill the syringe with the prescribed dose. - Administer directly from the dosing syringe. - Wash the syringe after use.

ORAL

Medical Information

**4.1 Therapeutic indications** Rupafin 1 mg/ml oral solution is indicated for the symptomatic treatment of: - Allergic rhinitis (including persistent allergic rhinitis) in children aged 2 to 11 years (see section 5.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). - Urticaria in children aged 2 to 11 years (see section 5.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).

**4.3 Contraindications** Hypersensitivity to rupatadine or to any of the excipients.

R06A X28

xr 06 a x 28

Manufacturer Information

HYPHENS PHARMA PTE. LTD.

ITALFARMACO, S.A.

Active Ingredients

Rupatadine fumarate 1.280 mg eqv rupatadine

1.00 mg/ml

Rupatadine

Documents

Package Inserts

Rupafin oral solution PI.pdf

Approved: March 6, 2017

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

RUPAFIN ORAL SOLUTION 1mg/ml - HSA Approval | MedPath